Infection, Pulmonary Disease, Chronic Obstructive
Conditions
Keywords
75 mg dose strength, Safety, Pharmacokinetics
Brief summary
The purpose of this study is to compare the safety and pharmacokinetics of ciprofloxacin after inhalation of single 52.5 and 48.75 mg doses in COPD patients. In this study the 48.75 mg dose will be administered for the first time using a new high dose strength (i.e. one capsule containing 75 mg powder = 48.75 mg ciprofloxacin) formulation. Safety investigations will focus on local tolerability in the lung and evaluate whether the patient can inhale the higher amount of powder compared to the lower dose strength. Pharmacokinetics is to see how the body absorbs, distributes, breaks down and gets rid of the study drug. Results from this study will be used to decide whether the new dose strength is suitable for larger clinical trials planned for the COPD patients population.
Interventions
DRUGCipro Inhale (Ciprofloxacin, BAYQ3939)
32.5 mg ciprofloxacin corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as single dose inhalation
Sponsors
Bayer
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Adult subjects with COPD, 40 - 75 years of age * All subjects must have a diagnosis of COPD and must have airway obstruction with a post-bronchodilator Forced Expiratory Volume in 1 sec (FEV1) of \>/= 30% and \<= 80% of predicted and a post-bronchodilator FEV1 / Forced Vital Capacity (FVC) of \</= 70% * Subjects must be current or ex-smokers with a smoking history of more than 10 pack-years * Subjects must be able to perform technically acceptable pulmonary function tests during the study period as required in the protocol * Subjects must be able to produce an sufficient amount of sputum during sputum induction at screening
Exclusion criteria
* Subjects with a significant respiratory disease other than COPD. * Exacerbation within 8 weeks prior to screening * Subjects with more than 1 COPD exacerbation within 12 months prior to screening * Subjects must have an FEV1 of at least one Liter * Subjects with a history or physician's diagnosis of asthma. If a patient has a total blood eosinophil count \>/= 0.6 x 10\^9/L source documentation is required to verify that the increased eosinophil count is related to a non-asthmatic condition. * Subjects with hypersensitivity to the ciprofloxacin or to other quinolones and/or to inactive constituents of the inhalation powder * Subjects with known hypersensitivity of the bronchial system to inhalation of nebulized drugs or saline solution * Subjects with a history of cystic fibrosis * Subjects with clinically evident bronchiectasis * Subjects taking any: * Oral beta-adrenergic drugs or non cardioselective beta blockers, * Oral glucocorticoids, * Antihistamines or antileukotrienes prescribed for asthma, * Oral cromolyn sodium or oral nedocromil sodium, * Concomitant inhalative therapy with antibiotics and / or concomitant systemic therapy with fluoroquinolones
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determination of ciprofloxacin pharmacokinetics derived from drug concentrations in blood, urine and sputum | Within 24 hours after treatment |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events collection | Within 30 days |
Countries
Germany
Outcome results
None listed